EndoChoice To Raise $115M In NYSE Offering

May 11, 2015 | The medical device company EndoChoice has filed with the SEC to raised $115 million in a NYSE IPO. The company is expected to be valued at around $500 million. EndoChoice is a US-based company that develops treatments for digestive tract disorders. The company has a development center in Israel with about 70 employees. EndoChoice was founded in 2008 by Mark Gilreath and Will Parks.